Effects of on cisplatin induced ocular toxicity: an experimental study.

Cisplatin is a widely used and highly effective anti-cancer agent and one of the limiting side effects of cisplatin is ocular toxicity. , also known as yarrow, is a plant that has been used for many years to treat various health problems including chemotherapy-related toxicities. The present investigation was designed to evaluate the biochemical, molecular and histopathological effects of on cisplatin-induced oxidative and inflammatory ocular damage in rats. Twenty-four adult male rats were assigned randomly to four groups () as (1) control, (2) cisplatin (7 mg/kg, intraperitoneally), (3) Cisplatin + (200 mg/kg, orally for 14 consecutive days), (4) Cisplatin + (400 mg/kg, orally for 14 consecutive days). Levels of total antioxidant capacity and total oxidant status, SOD, MDA, IL-1β, and IL-10 were measured in ocular tissue. The mRNA expressions of TNF-α, nuclear factor kappa B and Caspase-3 were evaluated. Also, ocular sections were evaluated histopathologically. upregulated ocular antioxidant enzymes and downregulated inflammation. The SOD activity and total antioxidant capacity increased whereas total oxidant status and MDA levels decreased significantly at high dose group. High dose treatment reduced the IL-1β concentrations, whereas IL-10 levels increased significantly in that group. Moreover, we observed that restored ocular histopathological structure and significantly suppressed apoptosis by reducing the expression of Caspase-3. Collectively, our results suggest that have protective effects against cisplatin-induced ocular toxicity and is a promising adjuvant therapy with the potential to prevent cisplatin related ocular toxicity.